相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
1
100.0%
暂无批准数据
- Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams. - Notable appointments include former CDC Director Dr. Julie Louise Gerberding joining ARTIDIS and former Roche neuroscience head Dr. Paulo Fontoura taking on dual advisory roles. - Companies ranging from clinical-stage biotechs to established pharmaceutical firms are adding expertise in areas including oncology, neuroscience, infectious diseases, and antimicrobial resistance.
- Actuate Therapeutics will present Phase II clinical trial data on elraglusib, their GSK-3β inhibitor, for advanced salivary gland carcinoma at the AACR Annual Meeting 2025 in Chicago. - Researchers report encouraging response rates in non-Adenoid Cystic Carcinoma patients with nuclear GSK-3β overexpression when elraglusib is combined with chemotherapy and immune priming. - A separate presentation from Brown University's Legorreta Cancer Center will showcase synergistic effects of combining elraglusib with Jazz Pharmaceuticals' investigational compounds ONC206 and ONC212 for solid tumors.
- Delta-like ligand 3 (DLL3) is emerging as a potential therapeutic target for aggressive neuroendocrine prostate cancer, which often develops resistance to standard treatments. - Early clinical trials of DLL3-targeted T cell engagers, such as MK-6070, have demonstrated promising anti-tumor activity in patients with relapsed or refractory neuroendocrine prostate cancer. - PET imaging with 89Zr-SC16 may help in detecting and quantifying DLL3 expression in tumors, potentially improving patient selection for DLL3-targeted therapies. - While tarlatamab showed limited efficacy in a broad neuroendocrine prostate cancer cohort, ongoing research focuses on refining patient selection and exploring combination strategies to enhance treatment outcomes.
- Volastra Therapeutics has dosed the first patient in a Phase Ib trial evaluating sovilnesib for platinum-resistant or refractory high-grade serous ovarian cancer, with the FDA granting Fast Track designation for this indication. - The randomized dose optimization study aims to establish the recommended Phase 2 dose of once-daily oral sovilnesib, addressing a significant unmet need in a patient population with poor treatment response rates. - Volastra is advancing two chemically differentiated KIF18A inhibitors—sovilnesib and VLS-1488—in parallel clinical trials, while also developing biomarker approaches to measure chromosomal instability through partnerships with Microsoft, Tailor Bio, and Function Oncology.
